Dermatan sulfate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Dermatan sulfate is a medication indicated to prevent deep vein thrombosis.
- Generic Name
- Dermatan sulfate
- DrugBank Accession Number
- DB15880
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 475.38
Monoisotopic: 475.064287314 - Chemical Formula
- C14H21NO15S
- Synonyms
- beta-Heparin
- Chondroitin sulfate B
- Chondroitinsulfuric acid type B
- Dermatan 4-sulfate
- Dermatan hydrogen sulfate
- Dermatan L-iduronate
- Dermatan sulfate, low molecular weight
- Dermatan sulphate
- External IDs
- MF 701
- MF-701
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Deep vein thrombosis •••••••••••• ••••• •••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Dermatan sulfate. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dermatan sulfate. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Dermatan sulfate is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dermatan sulfate. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Dermatan sulfate. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Dermatan sulfate sodium Not Available Not Available Not applicable
Categories
- ATC Codes
- B01AX04 — Dermatan sulfate
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J3OC7JVS54
- CAS number
- 24967-94-0
- InChI Key
- AVJBPWGFOQAPRH-FWMKGIEWSA-L
- InChI
- InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/p-2/t4-,5-,6+,7+,8-,9+,10-,11-,13-,14-/m1/s1
- IUPAC Name
- (2R,3S,4S,5R,6R)-6-{[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-(sulfonatooxy)oxan-4-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylate
- SMILES
- CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@@H]1O[C@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O
References
- General References
- AIFA Product Information: MISTRAL (dermatan sulfate) injection [Link]
- External Links
- ChemSpider
- 30361
- Wikipedia
- Dermatan_sulfate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular 100 MG/2ML Injection, solution Intramuscular 200 MG/2ML Injection, solution Intramuscular 300 MG/3ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -6.4 Chemaxon pKa (Strongest Acidic) -1.9 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 14 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 264.5 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 99.01 m3·mol-1 Chemaxon Polarizability 40.06 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 209.1875258 predictedDarkChem Lite v0.1.0 [M-H]- 187.47469 predictedDeepCCS 1.0 (2019) [M+H]+ 209.4681258 predictedDarkChem Lite v0.1.0 [M+H]+ 189.2996 predictedDeepCCS 1.0 (2019) [M+Na]+ 209.4400258 predictedDarkChem Lite v0.1.0 [M+Na]+ 194.90538 predictedDeepCCS 1.0 (2019)
Drug created at September 24, 2020 17:17 / Updated at December 01, 2022 11:30